Sharon Mates Intra Cellular Therapies, Inc. (ITCI) insider trading activity

ITCI Quotes by TradingView

Sharon Mates is Chairman and CEO of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 1.07 Million shares of ITCI, which is worth approximately $87.5 Million. The most recent transaction as insider was on Feb 23, 2022, when has been sold 22,589 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.07M
0% 3M change
1.91% 12M change
Total Value Held $87.5 Million

Sharon Mates Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 23 2022
BUY
Exercise of conversion of derivative security
-
22,589 Added 1.98%
1,117,056 Common Stock
Feb 22 2022
SELL
Open market or private sale
$1,541,610 $55.36 p/Share
27,847 Reduced 2.48%
1,094,467 Common Stock
Feb 18 2022
BUY
Exercise of conversion of derivative security
-
27,847 Added 2.42%
1,122,314 Common Stock
Jan 10 2022
SELL
Open market or private sale
$1,712,289 $40.87 p/Share
41,896 Reduced 3.69%
1,094,467 Common Stock
Jan 08 2022
BUY
Exercise of conversion of derivative security
-
41,896 Added 3.56%
1,136,363 Common Stock
Oct 18 2021
SELL
Open market or private sale
$327,680 $40.0 p/Share
8,192 Reduced 0.74%
1,094,467 Common Stock
Oct 15 2021
SELL
Open market or private sale
$1,615,680 $40.0 p/Share
40,392 Reduced 3.54%
1,101,584 Common Stock
Oct 15 2021
BUY
Exercise of conversion of derivative security
$3,053 $2.84 p/Share
1,075 Added 0.1%
1,102,659 Common Stock
Oct 14 2021
SELL
Open market or private sale
$56,640 $40.0 p/Share
1,416 Reduced 0.12%
1,141,976 Common Stock
Aug 23 2021
BUY
Exercise of conversion of derivative security
$28,400 $2.84 p/Share
10,000 Added 0.87%
1,143,392 Common Stock
Feb 19 2021
SELL
Open market or private sale
$1,088,539 $39.09 p/Share
27,847 Reduced 2.4%
1,133,392 Common Stock
Feb 18 2021
BUY
Exercise of conversion of derivative security
-
27,847 Added 2.34%
1,161,239 Common Stock
Jan 11 2021
SELL
Open market or private sale
$1,334,388 $31.85 p/Share
41,896 Reduced 3.56%
1,133,392 Common Stock
Jan 08 2021
BUY
Exercise of conversion of derivative security
-
41,896 Added 3.44%
1,175,288 Common Stock
Jan 04 2021
SELL
Open market or private sale
$1,506,789 $31.17 p/Share
48,341 Reduced 4.09%
1,133,392 Common Stock
Jan 03 2021
BUY
Exercise of conversion of derivative security
-
34,341 Added 2.82%
1,181,733 Common Stock
Dec 18 2020
BUY
Exercise of conversion of derivative security
$93,160 $2.74 p/Share
34,000 Added 2.88%
1,147,392 Common Stock
Nov 10 2020
SELL
Open market or private sale
$1,322,500 $26.45 p/Share
50,000 Reduced 4.3%
1,113,392 Common Stock
Nov 04 2020
SELL
Open market or private sale
$1,250,000 $25.0 p/Share
50,000 Reduced 4.12%
1,163,392 Common Stock
SM

Sharon Mates

Chairman and CEO
New York, NY

Track Institutional and Insider Activities on ITCI

Follow Intra-Cellular Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

News

Receive news related to Intra-Cellular Therapies, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ITCI